hormone replacement therapy tend to abruptly stop when diagnosed with endocrine-dependent cancers; and vasomotor symptoms are common with hormonal drugs such as tamoxifen or aromatase inhibitors. For Dr. Goldman, the key is to be sure that menopausal
Search Results
Life After Treatment: Quality-of-Life Concerns in Patients Treated for Cancer
Mindy E. Goldman
The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Josh Lauring, Ben Ho Park, and Antonio C. Wolff
cell lines and resensitize these cells to hormonal therapies, including tamoxifen and aromatase inhibitors. 20 , 23 , 25 - 28 In contrast, other studies have not found an increased sensitivity of LTED cells to dual PI3-kinase/mTOR inhibitors, and LTED
The Selection of Hormonal Therapy in Prostate Cancer: Who, When, and for How Long?
Charles J. Ryan and Eric J. Small
herbal supplement, PC-SPES vs. diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa) (Abstr #709) . Proc Am Soc Clin Oncol , 2002 ; 21 . 28 Glick JH Wein A Torri S . Phase II study of tamoxifen in
New Approaches to Endocrine Therapy for Breast Cancer
William J. Gradishar
were updated to indicate that women who are postmenopausal at diagnosis and received an AI for 5 years “can consider an AI for an additional 5 years.” 5 This includes women who received tamoxifen for 5 years and wish to extend endocrine therapy to 10
Decision-Making For Patients With Resectable Breast Cancer: Individualized Decisions For and By Patients and Their Physicians
Charles L. Loprinzi and Peter M. Ravdin
. Early Breast Cancer Trialists' Collaborative Group . Lancet 1998 ; 352 : 930 – 942 . 16 Anonymous : Tamoxifen for early breast cancer: An overview of randomized trials. Early Breast Cancer Trialists' Collaborative Group . Lancet 1998
Breast Cancer Risk Assessment: A Guide for Clinicians Using the NCCN Breast Cancer Risk Reduction Guidelines
Sofia D. Merajver and Kara Milliron
. 13 Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study . J Natl Cancer Inst 1998 ; 90 : 1371 – 1388 . 14 Rockhill B Spiegelman
Chemo- and Radiotherapy in Adjuvant Management of Optimally Debulked Endometrial Cancer
David Scott Miller, Gini Fleming, and Marcus E. Randall
Oncology Group study . J Clin Oncol 1996 ; 14 : 357 – 361 . 19 Fiorica JV Brunetto VL Hanjani P . Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers
Susan M. Domchek, Jill E. Stopfer, and Timothy R. Rebbeck
: 1358 – 1365 . 45. Narod SA Brunet JS Ghadirian P . Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group . Lancet 2000 ; 356 : 1876
Renaming Ductal Carcinoma in Situ: Would Removing “Carcinoma” Reduce Overtreatment?
Sara H. Javid, L. Christine Fang, Larissa Korde, and Benjamin O. Anderson
breast-conserving surgery followed by radiation therapy, or mastectomy. 11 - 14 Tamoxifen is also considered as possible adjuvant therapy for patients with estrogen receptor-positive DCIS, both for reduction of local recurrence risk after breast
NCCN Guidelines Updates: Breast Cancer
Melinda L. Telli, William J. Gradishar, and John H. Ward
tumors >0.5 cm, the NCCN Guidelines state as a category 1 recommendation that clinicians should “strongly consider the 21-gene assay.” The assay predicts the benefit of chemotherapy when added to tamoxifen as adjuvant therapy, regardless of menopausal
